Search Results

relapse or breast cancer death risks. Ki67 proliferation index has been implicated as a surrogate marker of response for neoadjuvant hormonal therapy. A score of 2.7 or less was regarded as complete cell cycle arrest ( Ma et al. 2015 ). The

neoadjuvant setting, clinical response rates range from 50 to 70% of patients ( Colleoni & Montagna 2012 ). Almost all patients with advanced or metastatic ER+ breast cancer will relapse if treated with endocrine therapy alone during the first few years of

Pearson's method. Differences in relapse-free survival, defined as biochemical recurrence, were assessed using the Kaplan–Meier plots and log-rank test. Differences were considered statistically significant when P was <0.05. Results SOCS2 expression

breast cancers ( Cancer Research UK 2017 ). Even for those treated at an early stage, there is still a significant risk of relapse, often several years later. This is particularly true of oestrogen receptor-positive breast cancers, which are at a

following surgery and none of these four subjects experienced relapse. Conversely, of the remaining 12 who did have detectable ctDNA, all but one experienced relapse ( Diehl et al . 2008 ). The above study was based on mutations and used a highly

preventing recurrence. Among 9856 patients allocated to monotherapy with either tamoxifen or an aromatase inhibitor, following a mean duration of follow-up of 5.8 years, aromatase inhibitor monotherapy decreased relapse rate from 12.6% (for tamoxifen) to 9

(as reviewed by Choi et al . 2018 ). Moreover, in the context of tumour relapse after chemotherapy, MRC1 hi , CXCR4 hi , Tie2 hi VEGFA + macrophages have been identified as tumour-supporting M2 macrophages localising in perivascular areas where

Introduction Many of the 1.7 million women diagnosed each year with breast cancer benefit from endocrine therapy ( May 2014 ). Introduced originally for the treatment of breast cancer patients who present or relapse following surgery with

has been found in ∼40% of the primary breast cancer cases and GPER expression, as an independent unfavorable factor, has been found to correlate with relapse-free survival in patients treated with TAM ( Filardo et al . 2006 , Ignatov et al . 2011

was further confirmed in publicly available datasets of mCRPC tissue samples from patients that suffered from relapse after docetaxel treatment ( Kumar et al. 2016 ). Our analysis revealed significantly increased p300 levels (1.5-fold) in patients